

Appln No.: 10/075,947  
Amendment Dated: July 12, 2004  
Reply to Office Action of March 25, 2004

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-10. (canceled)

11. (currently amended) T cells expressing a recombinant single chain peptide comprising the variable region of the light chain of an anti-G<sub>D2</sub> antibody linked to the variable region of the heavy chain of an anti-G<sub>D2</sub> antibody, wherein the recombinant single chain peptide is encoded by a polynucleotide comprising a region encoding the variable region of the light chain of an anti-G<sub>D2</sub> antibody linked to a region encoding the variable region of the heavy chain of an anti-G<sub>D2</sub> antibody, wherein the variable region of the light chain is linked to the variable region of the heavy chain in an orientation whereby a peptide expressed from the polynucleotide binds to G<sub>D2</sub>, and wherein the polynucleotide comprises, in contiguous sequence, the bases identified in SEQ. ID NO: 2.

12-22. (canceled)

23. (currently amended) T cells according to claim 11, expressing a recombinant single chain peptide comprising the variable region of the light chain of an anti-G<sub>D2</sub> antibody linked to the variable region of the heavy chain of an anti-G<sub>D2</sub> antibody, wherein the recombinant single chain peptide is encoded by a polynucleotide comprising a region encoding the variable region of the light chain of an anti-G<sub>D2</sub> antibody linked to a region encoding the variable region of the heavy chain of an anti-G<sub>D2</sub> antibody, wherein the variable region of the light chain is linked to the variable region of the heavy chain in an orientation whereby a peptide expressed from the polynucleotide binds to G<sub>D2</sub>, and wherein the polynucleotide comprises, in contiguous sequence, the bases identified in SEQ. ID NO: 1.

24-28. (cancelled)

29. (new) T cells according to claim 11, wherein the polynucleotide comprises, in contiguous sequence, the bases identified in SEQ. ID NO: 2.

30. (new) T cells according to claim 29, wherein the polynucleotide further encodes a therapeutic or pre-therapeutic moiety.

31. (new) T cells according to claim 30, wherein the pre-therapeutic moiety is a pro-drug

Appln No.: 10/075,947

Amendment Dated: July 12, 2004

Reply to Office Action of March 25, 2004

converting enzyme.

32. (new) T cells according to claim 30, wherein the pre-therapeutic moiety is streptavidin.

33. (new) T cells according to claim 30, wherein the therapeutic moiety is a toxin.

34. (new) T cells according to claim 23, wherein the polynucleotide further encodes a therapeutic or pre-therapeutic moiety.

35. (new) T cells according to claim 34, wherein the pre-therapeutic moiety is a pro-drug converting enzyme.

36. (new) T cells according to claim 34, wherein the pre-therapeutic moiety is streptavidin.

37. (new) T cells according to claim 34, wherein the therapeutic moiety is a toxin.

38. (new) T cells according to claim 11, wherein the polynucleotide further encodes a therapeutic or pre-therapeutic moiety.

39. (new) T cells according to claim 38, wherein the pre-therapeutic moiety is a pro-drug converting enzyme.

40. (new) T cells according to claim 39, wherein the pre-therapeutic moiety is streptavidin.

41. (new) T cells according to claim 39, wherein the therapeutic moiety is a toxin.